Immunomodulatory effects of IL-33 in atopic dermatitis

M
Matthew Turner, MD

Primary Investigator

Overview

The purpose of this study is to define the effects of neutralizing a certain protein affecting healthy and diseased skin and blood from patients with atopic dermatitis and to determine if the response to neutralization will differ between different subtypes of atopic dermatitis

Description

The purpose of this study is to define the effects of neutralizing a certain protein (IL-33) affecting healthy and diseased skin and blood from patients with atopic dermatitis and to determine if the response to neutralization will differ between different subtypes of atopic dermatitis.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    atopic dermatitis,healthy
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Active moderate to severe atopic dermatitis (AD) or healthy individuals who are similarly matched to enrolled AD patients in age, race, and sex
Exclusion Criteria
Systemic immunosuppressant in the past 6 months
Use of UVB or UVA phototherapies or tanning beds in the past 3 months
Use of topical steroids in/around biopsy sites >1 (preferably 2) week(s)
History of primary or secondary immunodeficiency disorders/diseases
History of keloid scar formation
History of allergy to lidocaine or other amide local anesthetics
History of bleeding disorders that could result in prolonged bleeding
History of prolonged or poor wound healing

Additional Information:
Participants will be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1508749599

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center